112results about How to "Improve cognitive impairment" patented technology

The invention relates to a medication composition and a process for preparation the invention which is for improving cerebral cognitive function disorder, preventing and curing senile dementia. The medication composition of the invention is composed of curcuma, ginkgo leaf and thinleaf milkwort root-bark which are prepared by the techniques of weighting, drying, crashing, marinating, poaching, ethanol extracting, condensing, merging and the like. The medication composition of the invention has the effects of opening the key to the mind, refreshing the brain, nourishing heart, invigorating the circulation of blood, recuperating yin and yang, and resisting senescence, which is capable of improving study memorizing ability, and overcoming cerebral cognitive function disorder, thereby preventing and curing senile dementia.

The invention provides a pharmaceutical composition for the prevention and treatment of ischemic cerebrovascular diseases and the preparation method thereof, which contains active ingredients and carriers, wherein the active ingredients consist of fumalic acid or the pharmaceutically acceptable salt and borneol with the weight ratio of 100: 0.5 to 10. The invention can be prepared into the pharmaceutical formulations which are applicable to the clinical application, and the formulations include: granules, capsules, tablets, dropping pills, suppositories and injections. The invention reveals the neuro-protective effect of the composition of fumalic acid or the salt and borneol for transient total cerebral ischemia, and the synergy of the two drugs is played by the combination of the two; compared with single fumalic acid, the absorption half-life is prolonged, the time for reaching peak is faster, the dosage of fumalic acid is reduced and the safety of the drugs is increased. The invention has the advantages of the complementary and synergy of pharmacological effects, instant effects, prolonged effective time, small dosage and precise efficacy when being taken as the drug for the prevention and treatment of ischemic cerebrovascular diseases.

The invention relates to a qingkailing preparation and the application of a composition of effective components thereof including baicalin, jasminoidin, cholic acid and mother of pearl to improving cognitive dysfunction, preventing and treating senile dementia. Morris water maze experiments prove that the qingkailing preparation and the effective components thereof can improve the cognitive dysfunction of senescence accelerated mice; an in-vivo experiments prove that the qingkailing preparation can improve plasticity change of Alzheimers disease model rats synapse damage resulting from A beta 1-42 hippocampal injection; an in vitro experiments prove that the qingkailing preparation and the composition of the effective components thereof including baicalin, jasminoidin, cholic acid and the mother of pearl can improve complete cerebral acetylcholine content of the senescence accelerated mice, can cause relative increment in the dopamine and serotonin levels of central nerve by staying the degradation of the acetylcholine, the dopamine and the serotonin, thus improving the intracerebral monoaminergic system activity, therefore, the Morris water maze experiments are possibly related to the effect of the qingkailing formula on improving the cognitive dysfunction and preventing and treating the senile dementia.

The invention discloses a benzo-aza-alkyl aryl piperazine derivative and applications in preparation of drugs. The derivative shows the effect on central nervous systems, especially on the double highaffinity activity of a 5-HT<1A> acceptor and a Sigma-1 acceptor. Various physiological and pharmacological effects are brought into play in the body; and the compound can be used as a pharmaceuticalactive substance, especially used for anti-depression, anti-anxiety, anti-bipolar affective disorder and anti-neuropathic pain, and can also be used as an intermediate to prepare other pharmaceuticalactive compounds. The compound is fast in effect and small in toxic and side effect, and can meet demands of clinical applications; and the compound is a compound or a free base or salt thereof havingthe following structural formula (IV). The structure of the compound or the free base or salt thereof is shown as the structural formula (IV).

The invention discloses an application of imatinib mesylate in preparation of drugs for resisting Parkinson's disease (PD). The application of imatinib mesylate (STI571) in preparation of drugs for treating neurodegenerative diseases belongs to the protective range of the invention, and the neurodegenerative diseases can be PD. An experiment proves that by continuous administration of the STI571, the dyskinesia induced by MPTP can be obviously improved, and the cognitive dysfunction of mice can be improved. The STI571 can obviously improve the dopaminergic neuron loss induced by the MPTP, can inhibit the rat CA1 and DG (diacylglycerol) region nerve cell apoptosis reaction induced by rotenone, can obviously inhibit the primary substantia nigra neuron apoptosis and Lewy protein expression induced by rotenone, and can inhibit the phosphorylation activation of PKC (Protein Kinase C) and Akt. The STI571 used as a specific inhibitor of c-Ab1 can resist the formation of PD, can improve the behavioral abnormity and cognitive dysfunction of PD, can be used as a new candidate drug for resisting neurodegenerative diseases such as PD and the like, and has favorable application prospects; and the clinical indications of the STI571 are greatly expanded.

The invention discloses a beta-carboline GSK3beta/DYRK1A dual inhibitor as shown in a general formula I, a preparation method of the beta-carboline GSK3beta/DYRK1A dual inhibitor and application of the beta-carboline GSK3beta/DYRK1A dual inhibitor in resistant the Alzheimer's disease. A novel beta-carboline derivative has GSK3beta/DYRK1A dual inhibition activity, and a preparation method of the beta-carboline derivative serving as the GSK3beta/DYRK1A dual inhibitor is provided. Meanwhile, the invention also discloses application of the beta-carboline derivative in preparation of a medicine for treating the Alzheimer's disease. The beta-carboline derivative can provide a theoretical basis for discovery of a novel AD treatment drug.

The invention relates to a medicinal composition, in particular to a composition comprising 4-hydroxyl-2-oxo-1-pyrrolidine acetamine and 2-borneol, and application of the composition in medicines for preventing and/or treating cognition impairment. The composition provided by the invention can remarkably improve a cerebral trauma neural function of a rat and can remarkably prolong the time of passive activities. The composition provided by the invention plays a role in improving dysmnesia of the rat, caused by scopolamine, and can remarkably improve cognitive disorder of the rat, caused by cerebral ischemia. The composition has a remarkable effect in preventing and/or treating cognition impairment.

The invention relates to a Chinese wampee fruit extract and application thereof in preparation of a medicine for preventing and treating an alzheimer disease. The prepared Chinese wampee fruit extract disclosed by the invention can be applied to the medicine for preventing and treating the alzheimer disease as a new method for preventing and treating the alzheimer disease. The medicine disclosed by the invention has the effects of resisting oxidation, inhibiting generation of Abeta, reducing activation of astrocyte cells, and protecting nerve cells, so that the cognitive disorder caused by the disease can be effectively relieved; and the Chinese wampee fruit extract has a relatively good effect on prevention and treatment of the alzheimer disease.

The invention discloses application of tetrahydroberberine in preparation of drugs used for treating senile dementia, which belongs to novel application of drugs. The dosage form of tetrahydroberberine may be a capsule, a tablet, a granule, a spraying agent, an injection or a pill, and tetrahydroberberine exerts a good curative effect on the senile dementia.

The invention provides an application of terazosin in a medicine for treating radioactive cognitive dysfunction. The terazosin is a pharmaceutical salt formed with terazosin as an active ingredient ora solvate thereof. The invention has the beneficial effects that whether the terazosin component can improve cognitive function damage and hippocampal neuron damage caused by whole brain irradiationis observed through experiments, and the terazosin component has certain neuroprotective effect in the occurrence and development process of radiation cognitive function damage.

The invention provides a formula of special clinical nutrients for people after narcotherapy. The formula is characterized by comprising the following components in parts by weight of 40-60 parts of protein, 5-15 parts of fat, 40-50 parts of carbohydrate, 15-25 parts of dietary fibers, 0.05-1.2 parts of macroelements, 0.01-0.05 part of trace elements, 0.005-0.03 part of fat-soluble vitamins, 0.008-0.2 part of water-soluble vitamins, 0.1-1 part of meal essence, 0.04-0.8 part of medicine-food homologous components, 0.1-3 parts of a natural plant compound and 0.06-1.32 parts of a new resource food. The invention further provides a preparation method of the formula of clinical nutrients. The formula of the clinical nutrients can provide balanced nutrient substances according to body states ofpatients after narcotherapy and various complication which can occur, can reduce complication of patients after narcotherapy and accelerate the restoration of the patients after narcotherapy.

The invention discloses a method for central targeting delivery of siRNA based on adipose tissue, which is characterized in that a virus vector loaded with siRNA is injected into adipose tissue of human or model animals, and the virus is adeno-associated virus, lentivirus or adenovirus. The invention further discloses application of the adipose tissue-based central targeted delivery siRNA, and the method is applied to treatment of Alzheimer's disease. The exosome secreted by organs of a host is used as a carrier, the restriction of a blood brain barrier in siRNA targeted delivery is overcome, the siRNA targeting BACE1 is effectively conveyed into neurons, A beta deposition is reduced, cognitive impairment of the Alzheimer's disease is improved, and the problems of immunogenicity and toxicity of a traditional siRNA delivery carrier are solved; the method is flexible and variable, simultaneous delivery of different siRNAs can be realized, a complex in-vitro exosome pre-assembly process is not needed, the cost and the risk are greatly reduced, and large-scale clinical application is facilitated.

The invention provides a cell subpopulation with a therapeutic effect on brain injury diseases and a preparation method thereof, and belongs to the field of biomedicine. The cell subpopulation is fromadult neural tissue or induced pluripotent stem cells; the cell subpopulation is detected by using specific markers including nidogen, PAX6, SOX2, vimentin, Musashi-1 and NGFR. The cell subpopulationis a single cell subpopulation, when a P5 generation is cultured in vitro, the purity can reach 90% or above, the cell activity is 95% or above, and the cell subpopulation can still keep good drynessand differentiation potential even if a 32nd generation is cultured through continuous passage; a neuronal death and inflammatory response after a brain injury can be reversed by adjusting an NF-kappaB pathway reaction, and the effect of inhibiting the proliferation of lymphocytes and immune cells is achieved.

The invention provides the application of miR-21 in the diagnosis and treatment of subarachnoid hemorrhage, and belongs to the technical field of biomedicine and molecular biology. According to the application of miR-21 in the diagnosis and treatment of subarachnoid hemorrhage, the potential therapeutic effects of mesenchymal stem cell exosomes in SAH are explored, particularly in the effect on cognitive function. It is proved that the mesenchymal stem cell exosomes can reduce early brain damage after SAH and improve the cognitive function. In the mechanism, it is demonstrated by the exosomesrich in miR-21 play an important role in mediating effect on inhibiting neuronal apoptosis. According to the application of miR-21 in the diagnosis and treatment of subarachnoid hemorrhage, it is actually proved that miR-21 in the mesenchymal stem cell exosomes reduces brain damage after SAH by inhibiting the neuronal apoptosis, the neural behavior is improved through a PTEN/Akt pathway, potentialnovel restorative treatment methods and strategies are provided for SAH patients with the risk of cognitive deficits, and thus the good practical application value is obtained.

The invention relates to the technical field of medicines, and discloses new application of pleutotus ostreatus polysaccharide for preventing and/or treating AD (Alzheimer diseases). The application is characterized in that the activity of in-vitro acetylcholinesterase is inhibited by the pleutotus ostreatus polysaccharide, the in-vitro AD resisting function is realized, the levels of three types of proteins, such as p-tau, p-GSK3 and Abeta, in a brain can be obviously decreased, and the cognitive disorder of an AD rat is improved; the level of acetylcholinesterase in the brain of the AD rat is decreased, and the obvious in-vivo AD resisting function is realized. The application has the advantages that a path is widened for treating and relieving the AD, and the significant meaning is realized.

The invention discloses a traditional Chinese medicine capable of treating epilepsy after cerebral infarction, and the traditional Chinese medicine provided by the invention is prepared from the following medicinal materials in parts by weight: 5-10 parts of radix bupleuri, 6-12 parts of radix rehmanniae, 6-12 parts of angelica sinensis, 10-20 parts of ligusticum wallichii, 8-15 parts of radix paeoniae rubra, 6-12 parts of peach kernels, 8-15 parts of safflower carthamus, 4-8 parts of auranti fructus, 4-8 parts of platycodon grandiflorum, 6-12 parts of radix achyranthis bidentatae, 10-20 parts of rhizoma gastrodiae, 6-12 parts of white atractylodes rhizome, 6-12 parts of rhizoma pinellinae praeparata, 10-20 parts of poria cocos, 8-15 parts of dried tangerine, 6-12 parts of batryticated silkworm, 4-8 parts of scorpion, 15-30 parts of calamus and 1-5 parts of amber. The traditional Chinese medicine is a creation and breakthrough in treating epilepsy, and has the characteristics of treating both principal and secondary aspect of disease according to attack features of the epilepsy after cerebral infarction, activating blood circulation and dispelling stasis, removing phlegm and restoring consciousness, having small toxic and side effects and no tolerance.

The invention discloses indole-heteroaromatic piperazine (piperidine) derivatives or officinal salt thereof. The indole-heteroaromatic piperazine (piperidine) derivatives or officinal salt has the following structure as shown in a formula. The compounds and compositions contained therein have activity to 5-HT reuptake, a 5-HT1A acceptor and a 5-HT7 acceptor, and can be applied to preparing novel anti-depression drugs.

The invention discloses a new compound medicament of the effective ingredients of traditional Chinese medicines used for curing senile dementia. The drug ingredients is mainly used for tonifying the kidney, tonifying qi, removing heat-phlegm and activating blood; the invention is prepared by the extraction of the effective ingredients which adopt epimedium, ginseng leaves and stems, roots of polygala tenuifolia and radix curcumae as raw materials, and has obvious therapeutic effects to the senile dementia, especially for Alzheimer' s disease.